Why Carta's public battle might be a private markets nightma

Carta’s latest scandal could be a turning point for the company—but its implications could ultimately be bigger than the embattled cap table unicorn.

Related Keywords

Washington , United States , Denver , Colorado , Fort Worth , Texas , New York , Rockville , Dallas , La Jolla , California , Emeryville , Boston , Massachusetts , Houston , Irvine , Westford , Liberty Hall , San Diego , Jeff Perry , Allie Garfinkle , Chris Thompson , Andreessen Horowitz , Joe Abrams , Ambrx Biopharma , Frank Ballantine , Sam Altman , Henry Ward , Thoma Bravo , Alex Phelan , Jessica Mathews , Noel Moldvai , Andrew Sabi , Alexandra Rogers , Boston Scientific , Yahoo , Frazier Life Sciences , Crinetics Pharmaceuticals , Centre Partners , Twitter , Rabobank , Johnson , Mont Eye Associates , Sake Holdings , Silicon Valley , Chief Revenue Officer Jeff Perry , Lightspeed Venture Partners , Term Sheet , Yahoo Finance , Big Tech , Should Sam Altman , South San Francisco Based , Alpha Wave Ventures , Future Ventures , Khosla Ventures , Life Sciences , Essential Capital , Stray Dog Capital , Select Fund , Quick Roofing , Dallas Fort Worth , Liberty Hall Capital Partners , Vistair Limited , Global Advisors , Oak Hill Capital , Transitions Wealth Management , Behavioral Framework , Innovation Partners , Gryphon Investors , Bucks Mont Eye Associates , Excellere Partners , Beyond Podiatry , New Baltimore , Humboldt Capital , Sozo Ventures , Investment Partners , New York City Based , Tug Fisher , Judah Levy , Spencer Marks , ,